Reporting Data Item

Business Justification

Definition

Note: Where ‘NHS Wales Data Dictionary’ the definition is as per the Data Dictionary.

Permissible Values

5. MULTI DISCIPLINARY TEAM OUTCOMES

5.0

ENCDv4.5b (5.1)

GOCI

Treatment plan discussed by the multi disciplinary team

Required for the audit of National Cancer Standards 2005 and required for the use of the Multi Disciplinary Meeting (MDM) module.

To record the fact that the care of this patient was formally reviewed by a specialist team.

•      Yes

•      No

5.1

Multi disciplinary meeting identifier

This item is required to audit against the National Cancer Standards 2005). Enables effective use of the Multi Disciplinary Meeting (MDM) module to facilitate direct patient care plans and validates data collection at source.

The operating identifier of the multi disciplinary meeting where the patient was discussed.

5.2

ENCDv4.5b (5.2)

Date treatment plan discussed by the multi disciplinary team

Required for the audit of the National Cancer Standards and submission to National / Welsh audits required for the use of the Multi Disciplinary Meeting (MDM) module.

The date that cancer care plan was discussed by the specialist team. The date of the discussed treatment plan (of the three listed under permissible values) will be utilised in order (where more than one permissible value is listed) as per the required output specifications.

Cancer Standards 2005

•      Date of the first treatment plan discussion

National / Welsh audits

•      Date treatment plan discussed, indicated as the most significant by the multi disciplinary team

•      Date of the last treatment plan discussion

5.3

ENCDv4.5b (5.5)

NOGCA

GOCI

Cancer treatment plan intent

To monitor treatment outcomes against local clinical policies and guidelines. To enable analysis of treatment planned versus treatment given. To monitor the number of cancer patients who received no specific anti-cancer treatment. This item is also required for the use of the multi Disciplinary Meeting (MDM) module.

The intention of the treatment which is planned for the patient at this point in time. It is appreciated that this decision may change as treatment is given and the patient’s response to this treatment is assessed. Definitions of the permissible values are as values:

•      Curative Treatment given with the potential for cure (radical treatment) even if the proportion of patients achieving long term disease control (> 2 years) is small

•      Palliative anti-cancer treatment given with the aim of symptom control. (Palliative intent relates to all intended palliative treatments and not just treatments intended to be delivered by the specialist palliative care team)

•      Supportive treatment: To sustain the patients and carers ability to cope with a chronic or deteriorating condition and including respite care

•      No specific anti-cancer treatment

Permissible values are agreed by the clinical steering groups and conform to the requirements of the reporting output specifications. Currently there is no explicit requirement to map to terminologies or classifications. This will be kept under review.

•      Curative

•      Palliative

•      Supportive treatment

•      No specific anti-cancer treatment

5.4

ENCDv4.5b (5.8)

Reason for no specific anti-cancer treatment

To monitor the reasons why cancer patients received no specific anti-cancer treatment. For the audit of the National Cancer Standards 2005 and is also required for the use of the Multi Disciplinary Meeting (MDM) module.

The reason why the patient did not receive any specific anti-cancer treatment. The permissible value ‘Unfit: poor performance status’ is dependent upon the output value for the ‘Final pre-treatment performance status agreed by the multi disciplinary team’.

Permissible values are agreed by the clinical steering groups and conform to the requirements of the reporting output specifications. Currently there is no explicit requirement to map to terminologies or classifications. This will be kept under review.

•      Patient declined treatment

•      Unfit: poor performance status

•      Unfit: significant co-morbidity

•      Unfit: advanced stage cancer

•      Unknown Primary Site

•      Died before treatment

•      No anti-cancer treatment available

•      Other

•      Watchful waiting

•      Reason not known

[multiple responses possible]

5.5

ENCDv4.5b (5.10)

NOGCA

Final pre-treatment performance status agreed by the multi disciplinary team

To allow for performance status to be taken into account in treatment decisions and in the analysis of treatment and outcome. This item is also required for the use of the Multi Disciplinary Meeting (MDM) module.

The patients’ performance status prior to treatment. If the permissible value is high and no anti-cancer treatment is given based on this value, it should be reflected in the reporting data item ‘Reason for no specific anti-cancer treatment’ and the permissible value ‘Unfit: poor performance status’ reported.

Refer to the WHO (World Health Organisation) / ECOG (Eastern Cooperative Oncology Group) scoring system

5.6

ENCDv4.5b (5.6)

NOGCA

Planned cancer treatment type

To determine the number of patients offered primary treatment types. To determine patterns of planned versus actual primary treatment types. To enable analysis of discrete groups of patients particularly where several modalities are planned. This item is also required for the use of the MDM module.

The type(s) of cancer treatments that is planned for the patient.

Permissible values are agreed by the clinical steering groups and conform to the requirements of the reporting output specifications. Currently there is no explicit requirement to map to terminologies or classifications. This will be kept under review.

•      Surgery

•      Teletherapy

•      Chemotherapy

•      Hormone therapy

•      Specialist palliative care

•      Brachytherapy

•      Biological

•      Active monitoring

•      Other

[multiple responses possible]

5.7

ENCDv4.5b (5.7)

NOGCA

Treatment type sequence

To determine patterns of planned primary treatment types. This item is also required for the use of the Multi Disciplinary Meeting (MDM) module.

The sequence in which the planned cancer treatment will be given. Planned treatment types are assigned a sequence number, the number will relate to the order the treatment is planned to be given e.g. radiotherapy 1, radiotherapy will be the first planned treatment. surgery 2. surgery will be the second planned treatment etc. For concurrent treatments such as chemo-radiotherapy both treatments should be assigned the same sequence number e.g. chemotherapy 1 and radiotherapy 1.

•      1

•      2

•      3

•      4

•      5

5.8

NOGCA

Planned cancer treatment sub type

To determine the number of patients offered primary treatment types. To determine patterns of planned versus actual primary treatment types. To enable analysis of discrete groups of patients particularly where several modalities are planned. Linked with reporting item 5.6 ‘Planned cancer treatment type’ to specify other relevant planned treatment types. Required for submission to the national oesophago-gastric cancer audit.

The specified other type(s) of cancer treatment that is planned for the patient.

Permissible values are agreed by the clinical steering groups and conform to the requirements of the reporting output specifications. Currently there is no explicit requirement to map to terminologies or classifications. This will be kept under review.

•      Endoscopic mucosal resection

•      Photodynamic therapy

•      Endoscopic palliative therapy: unspecified